https://atonco-pharma.com/science/ 2026-03-24T11:43:45+00:00 https://atonco-pharma.com/en/science/ 2026-03-24T11:43:45+00:00 https://atonco-pharma.com/en/science/clinical-experience-with-%ce%b1-particle-emitting-211at-treatment-of-recurrent-brain-tumor-patients-with-211at-labeled-chimeric-antitenascin-monoclonal-antibody-81c6/ 2008-01-27T14:42:41+00:00 https://atonco-pharma.com/en/science/211at-bc8-b10-followed-by-donor-stem-cell-transplant-in-treating-patients-with-relapsed-or-refractory-high-risk-acute-leukemia-or-myelodysplastic-syndrome/ 2018-09-14T13:56:00+00:00 https://atonco-pharma.com/en/science/pertinence-a-pilot-study-to-assess-safety-tolerability-radiation-dosimetry-and-imaging-properties-of-89zr-labeled-girentuximab-in-non-muscle-invasive-bladder-cancer/ 2021-05-21T09:48:00+00:00 https://atonco-pharma.com/en/science/ato-101-nmibc-feasibility-study/ 2025-03-31T12:26:14+00:00 https://atonco-pharma.com/en/science/first-in-human-study-of-211atnaat-as-targeted-%ce%b1-therapy-in-patients-with-radioiodine-refractory-thyroid-cancer-alpha-t1-trial/ 2025-09-25T13:50:00+00:00 https://atonco-pharma.com/en/science/development-of-psma-targeted-alpha-therapy-using-211atpsma-5/ 2025-11-27T14:48:11+00:00 https://atonco-pharma.com/en/science/ato-101-perseverance-eu-phase1/ 2025-12-03T14:03:44+00:00 https://atonco-pharma.com/science/first-in-human-study-of-211atnaat-as-targeted-%ce%b1-therapy-in-patients-with-radioiodine-refractory-thyroid-cancer-alpha-t1-trial/ 2025-12-06T11:56:47+00:00 https://atonco-pharma.com/science/clinical-experience-with-%ce%b1-particle-emitting-211at-treatment-of-recurrent-brain-tumor-patients-with-211at-labeled-chimeric-antitenascin-monoclonal-antibody-81c6/ 2025-12-06T12:50:13+00:00 https://atonco-pharma.com/science/ato-101-perseverance-eu-phase1/ 2025-12-06T14:05:38+00:00 https://atonco-pharma.com/science/ato-101-nmibc-feasibility-study/ 2025-12-06T14:08:46+00:00 https://atonco-pharma.com/science/pertinence-a-pilot-study-to-assess-safety-tolerability-radiation-dosimetry-and-imaging-properties-of-89zr-labeled-girentuximab-in-non-muscle-invasive-bladder-cancer/ 2025-12-23T10:08:37+00:00 https://atonco-pharma.com/science/211at-bc8-b10-followed-by-donor-stem-cell-transplant-in-treating-patients-with-relapsed-or-refractory-high-risk-acute-leukemia-or-myelodysplastic-syndrome/ 2025-12-23T10:09:44+00:00 https://atonco-pharma.com/science/211at-bc8-b10-before-donor-stem-cell-transplant-in-treating-patients-with-high-risk-acute-myeloid-leukemia-acute-lymphoblastic-leukemia-myelodysplastic-syndrome-or-mixed-phenotype-acute-leukemia/ 2025-12-23T10:12:25+00:00 https://atonco-pharma.com/science/pertinence-89zr-girentuximab-imaging-in-non-muscle-invasive-bladder-cancer/ 2026-02-11T15:02:15+00:00 https://atonco-pharma.com/science/development-of-psma-targeted-alpha-therapy-using-211atpsma-5/ 2026-02-16T12:19:37+00:00 https://atonco-pharma.com/en/science/211at-bc8-b10-before-donor-stem-cell-transplant-in-treating-patients-with-high-risk-acute-myeloid-leukemia-acute-lymphoblastic-leukemia-myelodysplastic-syndrome-or-mixed-phenotype-acute-leukemia/ 2026-03-06T17:37:48+00:00 https://atonco-pharma.com/en/science/pertinence-89zr-girentuximab-imaging-in-non-muscle-invasive-bladder-cancer/ 2026-03-07T06:38:24+00:00 https://atonco-pharma.com/science/non-muscle-invasive-bladder-cancer/ 2026-03-24T11:43:35+00:00 https://atonco-pharma.com/en/science/non-muscle-invasive-bladder-cancer/ 2026-03-24T11:43:45+00:00